TheraRadar
← Back
Data updated: Jun 28, 2026

AIR LIQUID INDUSTRIAL US LP

Pharma
Pharmaceuticals

AIR LIQUID INDUSTRIAL US LP is a pharmaceutical company with 1 FDA-approved products.

2013
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

AIR LIQUID INDUSTRIAL US LP's Key Drugs

AIR LIQUID INDUSTRIAL US LP's core commercial portfolio centers on OXYGEN, USP — its most strategically important drugs approved in the last 15 years.

AIR LIQUID INDUSTRIAL US LP's Recent FDA Approvals

New NDA/BLA approvals for AIR LIQUID INDUSTRIAL US LP over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

AIR LIQUID INDUSTRIAL US LP's Therapeutic Areas

Disease areas where AIR LIQUID INDUSTRIAL US LP has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

AIR LIQUID INDUSTRIAL US LP Pipeline Snapshot

Active clinical trials for AIR LIQUID INDUSTRIAL US LP across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • OXYGEN, USP leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Active trial monitoring
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling